Literature DB >> 23617776

Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis.

Sherveen S Salek1, Henry A Leder, Nicholas J Butler, Theresa J Gan, James P Dunn, Jennifer E Thorne.   

Abstract

PURPOSE: To describe the effectiveness of periocular corticosteroid injections for the control of intraocular inflammation associated with noninfectious uveitis.
METHODS: A total of 81 patients (109 eyes) who received a periocular injection were evaluated for active inflammation, visual acuity, intraocular pressure, degree of intraocular inflammation, and the presence of ocular complications, including macular edema.
RESULTS: Of all eyes, 36% (95%CI: 25%, 45%) demonstrated clinical resolution of inflammation at the 1-month visit after first injection, and 48% (95%CI: 37%, 59%) at 3 months. For multiple injections, 50% (95%CI: 28%, 72%) demonstrated resolution of inflammation at 1 month after the last injection, and 41% (95%CI: 20%, 63%) resolution of inflammation at 3 months after the last injection. Of the 49 eyes that initially responded, the estimated median time to recurrence was 7.6 months.
CONCLUSIONS: Approximately half of the treated eyes had resolution of intraocular inflammation at 3 months after corticosteroid injection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23617776     DOI: 10.3109/09273948.2013.767353

Source DB:  PubMed          Journal:  Ocul Immunol Inflamm        ISSN: 0927-3948            Impact factor:   3.070


  6 in total

1.  Intracellular delivery of dendrimer triamcinolone acetonide conjugates into microglial and human retinal pigment epithelial cells.

Authors:  Siva P Kambhampati; Manoj K Mishra; Panagiotis Mastorakos; Yumin Oh; Gerard A Lutty; Rangaramanujam M Kannan
Journal:  Eur J Pharm Biopharm       Date:  2015-02-19       Impact factor: 5.571

2.  Periocular corticosteroid injections in uveitis: effects and complications.

Authors:  H Nida Sen; Susan Vitale; Sapna S Gangaputra; Robert B Nussenblatt; Teresa L Liesegang; Grace A Levy-Clarke; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; John H Kempen
Journal:  Ophthalmology       Date:  2014-07-11       Impact factor: 12.079

Review 3.  Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives.

Authors:  Sherif A Gaballa; Uday B Kompella; Omar Elgarhy; Ali M Alqahtani; Barbara Pierscionek; Raid G Alany; Hamdy Abdelkader
Journal:  Drug Deliv Transl Res       Date:  2021-06       Impact factor: 4.617

Review 4.  Management of chronic ocular sarcoidosis: challenges and solutions.

Authors:  Artemis Matsou; Konstantinos T Tsaousis
Journal:  Clin Ophthalmol       Date:  2018-03-19

5.  Real-world evidence of treatment for relapse of noninfectious uveitis in tertiary centers in Japan: A multicenter study.

Authors:  Masaru Takeuchi; Takayuki Kanda; Toshikatsu Kaburaki; Rie Tanaka; Kenichi Namba; Koju Kamoi; Kazuichi Maruyama; Etsuko Shibuya; Nobuhisa Mizuki
Journal:  Medicine (Baltimore)       Date:  2019-03       Impact factor: 1.889

6.  Subtenon Triamcinolone Acetonide Injection with Topical Anesthesia in Pediatric Non-Infectious Uveitis.

Authors:  Jennifer L Jung; Mariana Harasawa; Jennifer L Patnaik; Alan G Palestine
Journal:  Ophthalmol Ther       Date:  2022-02-18
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.